Document is current
Any future updates will be listed below
-
Authors
Hughes, Michael https://orcid.org/0000-0003-3361-4909
Huang, Suiyuan
Pauling, John D
Sabbagh, Maya
Khanna, Dinesh
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (K24 AR AR063120)
- License Information
-
More Information
Article History
Received: 11 April 2022
Revised: 6 May 2022
Accepted: 8 May 2022
First Online: 18 May 2022
Declarations
:
: The study was approved with exempt status by the University of Michigan IRB (Study ID: HUM00175143; OHRP IRB Registration Number(s): IRB00000246).
: Michael Hughes—reports speaking fees from Actelion pharmaceuticals, Eli Lilly, and Pfizer, outside of the submitted work (all <$10,000). He is a member of a Data and Safety Monitoring Board for Certa Therapeutics. Suiyuan Huang—no reported conflicts of interest or competing interests. John Pauling—reports personal fees from Boehringer Ingelheim, Astra Zenaca, Sojournix Pharma and Permeatus Inc.; grants, personal fees, and non-financial support from Janssen; all outside the submitted work (<$10,000 for all honoraria / speaker fees). Maya Sabbagh—no reported conflicts of interest or competing interests. Dinesh Khanna—consulting fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe Pharma, Prometheus, Theraly; Dr. Khanna is Chief Medical Officer of Eicos Sciences, Inc, a subsidiary of CiviBioPharma and has stock options.
